Trial Profile
Treatment patterns and survival in ALK-positive (ALK+) advanced or metastatic non-small cell lung cancer canadian patients who discontinue crizotinib treatment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jul 2016
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Jul 2016 New trial record
- 07 Jun 2016 Results (n=49) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology